KIRKLAND, QC – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Health Canada approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with carboplatin and… Read More
David Leitch is, in his words, a chemical cartographer. And now, as a recipient of the prestigious 2025 Dorothy Killam Fellowship, he is poised to map a new route in… Read More
TOKYO, JP – PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as “PHC”), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse… Read More
STEMCELL Technologies Canada Inc. to build two new cutting-edge biomanufacturing facilities to produce critical inputs used in the development and manufacture of vaccines, therapeutics and diagnostic technologies BURNABY, BC –… Read More
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously announced, oral DehydraTECH-tirzepatide also reduced adverse… Read More
